IMUX Stock Overview
A biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Immunic, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.18 |
| 52 Week High | US$2.11 |
| 52 Week Low | US$0.97 |
| Beta | 1.88 |
| 11 Month Change | -15.11% |
| 3 Month Change | -16.01% |
| 1 Year Change | 0.85% |
| 33 Year Change | -85.82% |
| 5 Year Change | -83.99% |
| Change since IPO | -95.11% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate
Oct 25
Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation
Jan 22Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely
Oct 13Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely?
Jun 27Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo
Oct 20Immunic stock gains on $60M oversubscribed PIPE financing
Oct 10Immunic GAAP EPS of -$0.72 in-line
Aug 04Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely
Jul 27Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?
Apr 13Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?
Dec 24Here's Why We're Watching Immunic's (NASDAQ:IMUX) Cash Burn Situation
Aug 13We're Hopeful That Immunic (NASDAQ:IMUX) Will Use Its Cash Wisely
May 10Immunic EPS misses by $0.95
May 06Immunic EPS misses by $0.07
Nov 05Enrollment underway in Immunic's Phase 2 part of IMU-838 study in COVID-19
Nov 02Immunic (IMUX) Investor Presentation - Slideshow
Oct 31Shareholder Returns
| IMUX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.3% | 4.0% | 2.2% |
| 1Y | 0.9% | 18.3% | 32.6% |
Return vs Industry: IMUX underperformed the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: IMUX underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| IMUX volatility | |
|---|---|
| IMUX Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IMUX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IMUX's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 85 | Daniel Vitt | imux.com |
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases.
Immunic, Inc. Fundamentals Summary
| IMUX fundamental statistics | |
|---|---|
| Market cap | US$99.09m |
| Earnings (TTM) | -US$96.90m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.1x
P/E RatioIs IMUX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMUX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$96.90m |
| Earnings | -US$96.90m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.08 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did IMUX perform over the long term?
See historical performance and comparison